Nurse Practitioner Program year 2025 Source: CMS Open Payments, 2026 publication

Kristi Slack

Nurse Practitioner Marietta, MS Nurse Practitioner

NPI 1003840232 CMS profile 10636256

3 County Road 4050, Marietta, MS 38856

Open in the dashboard

General payments

$145

7 records reported · program year 2025

Research payments

$0

Paid to them · None reported · program year 2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristi Slack of Marietta, MS is reported in the CMS Open Payments database as having received $145 across 7 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 33rd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2025 General $145 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristi Slack
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Kristi Slack were reported at $145. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Kristi Slack Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $0 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $145 $174 $55–$557 $169

Breakdown

Who paid General payments · program year 2025
  1. Sobi, Inc $29 1 payment
  2. Janssen Biotech, Inc. $23 1 payment
  3. Genentech USA, Inc. $22 1 payment
  4. Takeda Pharmaceuticals U.S.A., Inc. $21 1 payment
  5. Merck Sharp & Dohme Corporation $19 1 payment
  6. BridgeBio Pharma, Inc. $16 1 payment
  7. Bayer HealthCare Pharmaceuticals Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program year 2025
  1. Food and Beverage $145 7 payments
Products named General payments · program year 2025
  1. VONJO $29 1 payment
  2. ERLEADA $23 1 payment
  3. BALVERSA $23 1 payment
  4. AKEEGA $23 1 payment
  5. VENCLEXTA $22 1 payment
  6. HYQVIA $21 1 payment
  7. LYNPARZA $19 1 payment
  8. Attruby $16 1 payment
  9. Kerendia $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

489

Median for Nurse Practitioner: 389

Drug cost

$6,171

Median for Nurse Practitioner: $21,885

Branded share of claims

22.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Symbicort Budesonide/Formoterol Fumarate Brand 11 $2,480
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 52 $442
Albuterol Sulfate Hfa Albuterol Sulfate Brand 15 $359
Clindamycin Hcl Generic 42 $359
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 20 $257
Meloxicam Generic 12 $218
Ropinirole Hcl Generic 15 $218
Cephalexin Generic 11 $186
Azithromycin Generic 38 $185
Atorvastatin Calcium Generic 24 $175

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$17,050

Of which drugs: $1,648

Medicare patients

127

Average age 72

Services billed

771

72 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 39%
Ischemic heart disease 30%
Diabetes 28%
Depression 16%
Chronic kidney disease 14%
Heart failure 13%
COPD 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 13 13 $862
Injection, lincomycin hcl, up to 300 mg J2010 Office 78 117 $724
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 83 132 $10

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

7 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record